Moomoo AI 已提取核心信息
On January 8, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced two significant developments. Firstly, the company disclosed that it had regained compliance with the Nasdaq Listing Rule 5550(a)(2) concerning the minimum bid price requirement. This follows a previous notification on November 3, 2023, indicating that Compugen's shares had fallen below the $1.00 minimum bid price over 30 consecutive business days. The company successfully maintained a closing bid price of at least $1.00 for 10 consecutive business days from December 19, 2023, to January 3, 2024, which led to the restoration of compliance. Secondly, Compugen revealed that it is set to receive a $10 million milestone payment from AstraZeneca. This payment was triggered by the dosing of the first patient in AstraZeneca's Phase 3 trial of rilvegostomig for biliary tract cancer. Rilvegostomig is a PD-1/TIGIT bispecific antibody developed from Compugen's COM902 antibody, which is part of a licensing agreement with AstraZeneca for the development of bispecific and multispecific antibodies. Compugen specializes in computational target discovery for cancer immunotherapies and has a pipeline of proprietary and partnered therapeutic programs.
On January 8, 2024, Compugen Ltd., a clinical-stage cancer immunotherapy company, announced two significant developments. Firstly, the company disclosed that it had regained compliance with the Nasdaq Listing Rule 5550(a)(2) concerning the minimum bid price requirement. This follows a previous notification on November 3, 2023, indicating that Compugen's shares had fallen below the $1.00 minimum bid price over 30 consecutive business days. The company successfully maintained a closing bid price of at least $1.00 for 10 consecutive business days from December 19, 2023, to January 3, 2024, which led to the restoration of compliance. Secondly, Compugen revealed that it is set to receive a $10 million milestone payment from AstraZeneca. This payment was triggered by the dosing of the first patient in AstraZeneca's Phase 3 trial of rilvegostomig for biliary tract cancer. Rilvegostomig is a PD-1/TIGIT bispecific antibody developed from Compugen's COM902 antibody, which is part of a licensing agreement with AstraZeneca for the development of bispecific and multispecific antibodies. Compugen specializes in computational target discovery for cancer immunotherapies and has a pipeline of proprietary and partnered therapeutic programs.
2024年1月8日，临床阶段的癌症免疫疗法公司Compugen有限公司宣布了两项重大进展。首先，该公司透露已恢复遵守纳斯达克上市规则5550（a）（2）中关于最低出价要求的要求。在此之前，Compugen于2023年11月3日发布了一份通知，表明Compugen的股票在连续30个工作日内跌破了1.00美元的最低出价。从2023年12月19日至2024年1月3日，该公司成功地连续10个工作日将收盘价维持在至少1.00美元，这导致合规性恢复。其次，Compugen透露，它将从阿斯利康获得1000万美元的里程碑式付款。这笔付款是由阿斯利康针对胆道癌的rilvegostomig三期试验中第一位患者给药...展开全部
2024年1月8日，临床阶段的癌症免疫疗法公司Compugen有限公司宣布了两项重大进展。首先，该公司透露已恢复遵守纳斯达克上市规则5550（a）（2）中关于最低出价要求的要求。在此之前，Compugen于2023年11月3日发布了一份通知，表明Compugen的股票在连续30个工作日内跌破了1.00美元的最低出价。从2023年12月19日至2024年1月3日，该公司成功地连续10个工作日将收盘价维持在至少1.00美元，这导致合规性恢复。其次，Compugen透露，它将从阿斯利康获得1000万美元的里程碑式付款。这笔付款是由阿斯利康针对胆道癌的rilvegostomig三期试验中第一位患者给药引发的。Rilvegostomig是一种由Compugen的 COM902 抗体开发的PD-1/TIGIT双特异性抗体，该抗体是与阿斯利康签订的开发双特异性和多特异性抗体的许可协议的一部分。Compugen专门研究癌症免疫疗法的计算靶标发现，并拥有一系列专有和合作的治疗项目。
有用
没用